Clinical Trials Logo

Clinical Trial Summary

Opioid use disorder (OUD) is a treatable medical illness with three medications FDA approved for treatment. However, persons with OUD report significant sleep disturbance, even when treated with medications for opioid use disorder, leading to high rates of relapse. In this project, we will investigate a special set of photosensitive neurons in the retina as an underlying mechanism for circadian rhythm and sleep disturbance from opioid use and medications for OUD that could lead to novel intervention and improve treatment outcomes.


Clinical Trial Description

Three medications for OUD (MOUD) are FDA-approved and regularly used to treat OUD: methadone, buprenorphine, and extended-release naltrexone (XR-NTX). However, persons who use opioids, including those prescribed MOUDs, report sleep disruption. In addition to the sleep centers of the brain, mu opioid receptors (MORs) are also expressed in the retina (including the human retina), specifically in ganglion cells that are critically important for non-image forming photoreception including circadian regulation of sleep-wake behavior. Pre-clinical studies show that activation of MORs on these intrinsically photosensitive retinal ganglion cells (ipRGCs) reduces the electrophysiological response to light, impacting critical ipRGC functions such as synchronization of sleep-wake behavior and circadian rhythms to light (photoentrainment), light-induced melatonin suppression, and the post-illumination pupillary reflex (PIPR). Together, these results suggest that activation of MORs in the ipRGCs by opioid use and/or MOUDs may impair downstream ipRGC functions. This multi-disciplinary study will examine the novel overarching hypothesis that persistent alterations in sleep/wake behavior in OUD patients undergoing treatment are mediated by impaired ipRGC function, and biomarkers of this pathway can predict recovery and relapse. Three aims will be tested in a sample of 200 participants, 150 of whom will be engaged in MOUD therapy (e.g., 50 each on methadone, buprenorphine, and XR-NTX, respectively) and 50 of whom will be non-opioid using control participants. Aim 1 will test the hypothesis that MOUD differentially impacts function of ipRGC responses. Aim 2 will examine whether MOUD differentially impacts daytime sleepiness, daily sleep-wake behavior, sleep architecture, and sleep-disordered breathing. Finally, Aim 3 will determine if ipRGC function predicts opioid relapse among MOUD groups at 1-, 3- and 6- month follow-up. Compared to non-opioid using controls or persons receiving an opioid antagonist (XR-NTX), we predict that participants who are receiving an agonist (methadone) or partial-agonist (buprenorphine) MOUD will have the most ipRGC interference, as evidenced by reduced PIPR, attenuated light-induced melatonin suppression, reduced circadian rhythmic amplitude, increased sleep latency, and increased sleep fragmentation. Importantly, we hypothesize that impaired ipRGC function will predict worse treatment outcomes as indicated by opioid use by 6-month follow-up. Finally, an exploratory aim will examine whether the MOUD groups show different relationships between opioid craving/withdrawal symptoms and sleep-wake behavior over a 10-day assessment of the participants' daily lives within the normal environment. The results of this study will be highly significant because it would support the use of the pupillary response to light and other indicators of ipRGC function as novel biomarkers to predict the response and outcomes to MOUDs. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06104280
Study type Interventional
Source University of Alabama at Birmingham
Contact Karen Cropsey, PsyD
Phone 205-975-7809
Email kcropsey@uabmc.edu
Status Not yet recruiting
Phase N/A
Start date September 1, 2024
Completion date January 1, 2029

See also
  Status Clinical Trial Phase
Completed NCT04959214 - The Effect Of Progressıve Relaxatıon Exercıses N/A
Recruiting NCT05820919 - Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase N/A
Completed NCT05555186 - The Effects of Bright Light Therapy on Adolescent's Sleep Quality and Well-being N/A
Completed NCT05093465 - A Comparison of Two Behavioral Sleep Interventions Among College Students (ProjectTECH) N/A
Completed NCT03673397 - The Acute Effect of Aerobic Exercise on Sleep in Patients With Depression N/A
Recruiting NCT04368416 - Anxiety/Depression, Sleep and Alcohol in Elderly Anxiety/Depression, Sleep Disturbances and Alcohol Use Disorder in Elderly With Cognitive Complaints
Completed NCT04566822 - Calm Sleep Coaching N/A
Not yet recruiting NCT06406309 - Settling Down for Sleep in ADHD: The Impact of Sensory and Arousal Systems on Sleep in ADHD N/A
Recruiting NCT00860756 - Sleep Disturbance in Deployed Soldiers Phase 0
Recruiting NCT05699837 - Alpha Entrainment for Pain and Sleep (Extension) N/A
Completed NCT06108115 - Smartphone-Based Intervention for Sleep Disturbance in Individuals Recovering From Alcohol Use Disorder N/A
Completed NCT05511818 - Radicle Rest: A Study of Cannabinoids on Sleep and Health Outcomes N/A
Completed NCT04560595 - Remote Guided Caffeine Reduction N/A
Enrolling by invitation NCT04290650 - Sleep Disturbances in Patients With Psychotic Symptoms (AkuSleep) N/A
Recruiting NCT04207502 - Integrating Systematic Data of Geriatric Medicine to Explore the Solution for Health Aging
Suspended NCT03908905 - Sleep Disturbances and Chronic Widespread Pain
Completed NCT03269760 - Multimodal Sleep Pathway for Shoulder Arthroplasty Phase 1
Completed NCT04990206 - Improving Sleep Health in Adults With Overweight or Obesity N/A
Completed NCT03112824 - Functional Assessment of Ashwagandaha Root Extract During Weight Loss N/A
Completed NCT04776304 - Art Therapy qEEG Study for Service Members With a Traumatic Brain Injury and Posttraumatic Stress Symptoms N/A